Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1656 participants.
Also called NCT05491200
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,656 participants
- Sponsor
- Registry
-
NCT05491200
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Belgium, Czechia, Germany, Italy, Netherlands, Serbia
- Registry status
- Recruiting
Technical summary
Registry record NCT05491200. Randomized; no masking; primary purpose treatment. Start 2022-07-22 (actual); primary completion 2027-08-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
- Condition
- ST Elevated Myocardial Infarction
- Condition
- Dual Antiplatelet Therapy
- Intervention (Drug)
- Prasugrel based short DAPT
- Intervention (Drug)
- Prasugrel based standard DAPT
- Intervention (Device)
- OCT guided revascularization
- Intervention (Device)
- Angio guided revascularization
- Lead sponsor
- Research Maatschap Cardiologen Rotterdam Zuid
- Collaborator
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct05491200- Content hash
467662d76502ba88dda5205090668e769fe3957449216c1dee2af44732ea0454